HOME >> BIOLOGY >> NEWS
Celebrex may be safe for preterm labor, preliminary study finds

St. Louis, Sept. 23, 2002 -- The drug celecoxib may be a safer alternative for treating preterm labor than traditional therapies, according to a preliminary study led by Washington University School of Medicine in St. Louis. The study is published at the end of the month in the September issue of the American Journal of Obstetrics and Gynecology, and appears on the journal's website today.

One of the established treatments to prevent preterm delivery is indomethacin, a drug used to slow uterine contractions and delay delivery. But indomethacin is associated with severe side effects. Recent research suggests that celecoxib, also known as celebrex, may be a safer alternative. This study is the first clinical trial testing celecoxib in pregnant women.

"Celecoxib appears to be safer, particularly for the fetus," says Yoel Sadovsky, M.D., director of the Division of Genetics, Maternal-Fetal Medicine and Ultrasound at the School of Medicine. "These preliminary results also suggest that celecoxib is just as effective, and we are currently planning a larger trial to further examine its effectiveness."

The study was a combined effort between Washington University and Northwestern University. Sadovsky, also associate professor of obstetrics and gynecology and of cell biology and physiology, led the study. The first authors are Catherine S. Stika, M.D., at Northwestern University and Gilad A. Gross, M.D., assistant professor of obstetrics and gynecology at Washington University.

According to the American College of Obstetrics and Gynecology, about 1 in every 10 births in the United States occurs within the first 37 weeks of pregnancy and therefore is considered "preterm." Preterm labor is responsible for about 75 percent of newborn deaths not related to birth defects, and preterm infants often experience life-long complications.

Indomethacin, one of the standard drugs used to treat preterm labor, prevents the production of a type of p
'"/>

Contact: Gila Z. Reckess
reckessg@msnotes.wustl.edu
314-286-0109
Washington University School of Medicine
23-Sep-2002


Page: 1 2

Related biology news :

1. Case researchers substantiate bacterial link to preterm birth through mice studies
2. New ACOG guidelines on progesterone to prevent preterm birth praised by March of Dimes
3. Preeclampsia linked with higher risk of preterm delivery
4. Preeclampsia linked with higher risk of preterm delivery and later-life vascular disease
5. Predicting preterm birth still nearly impossible, study in New England Journal finds
6. Fetal lungs provide a signal initiating labor, UT Southwestern researchers find
7. Two-drug approach might shorten painful labor, reduce Caesarean sections
8. Society report encourages preliminary sex analysis of clinical trial data
9. Contract bridge enhances the immune system, according to a preliminary study by researchers at UC Berkeley
10. Novel anti-cancer agent shows minimal side effects with preliminary evidence of tumor shrinkage
11. Student science contest participation influences study, career choices, alumni say

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/5/2019)... (PRWEB) , ... November 05, 2019 , ... ... Amato Dentistry, providing state-of-the-art cosmetic and restorative dentistry to Seattle, WA, including ... Doctor of Dental Surgery degree from the University of Washington, Dr. Kopp is ...
(Date:10/30/2019)... ... October 29, 2019 , ... LGC Maine ... ATELLICA® analyzers, Order Numbers 701sa & 704sa. The kits, in a human-urine matrix, ... UUN. , Each VALIDATE® kit, liquid, ready-to-use, and prepared using the CLSI EP06-A ...
(Date:10/30/2019)... ... October 30, 2019 , ... Amberdata Inc., the leading ... including Fenbushi Capital, DF Capital, Rising Tide Fund, and HWVP. The new ... further accelerate its position as the leading data provider of institutional-grade blockchain and ...
Breaking Biology News(10 mins):
(Date:11/12/2019)... (PRWEB) , ... November 12, 2019 , ... ... ingredient solutions for the food and beverage industry launched a new innovative website. ... the digital experience. Now, the website offers global visitors updated ingredient usage tables ...
(Date:11/9/2019)... ... November 08, 2019 , ... ... technology for use in pathology research, today announced the results of analyses ... patients enrolled in the phase 3 selonsertib studies (STELLAR). Strong correlations were ...
(Date:11/5/2019)... ... November 04, 2019 , ... ... development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health ... GPEx® Boost. The technology enhances Catalent’s proven GPEx expression platform through multiple ...
(Date:11/2/2019)... ... 2019 , ... A clinical trial usually involves many different ... principal investigators, supply chain managers, manufacturers, IRT, CRAs and so on. Lack of ... data, potentially leading to patient risk. , By having a single source of ...
Breaking Biology Technology:
Cached News: